Skip to main
ESLA

ESLA Stock Forecast & Price Target

ESLA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Estrella Immunopharma Inc has recently completed an $8 million financing and advanced EB103 into the Phase II portion of its ongoing Phase I/II study, which significantly strengthens its clinical and financial position. The STARLIGHT-1 trial has received an independent recommendation to proceed into Phase II, marking a critical milestone that supports operational momentum and broadens patient access as they gather more safety and efficacy data. Additionally, Estrella's innovative ARTEMIS platform is poised to unlock new market opportunities in both B-cell malignancies and solid tumors, positioning the company favorably in the rapidly evolving field of immunotherapy.

Bears say

The negative outlook on Estrella Immunopharma's stock is primarily driven by concerns regarding potential dilution following indications that management will discuss broader strategic priorities, including pipeline development and partnerships at the upcoming shareholders meeting. The downward adjustment in target price from $16.00 to $8.00 reflects a conservative stance in light of evolving assumptions around the company's financial outlook. Furthermore, the company faces competitive challenges with its therapies targeting relapsed/refractory B-cell Non-Hodgkin's Lymphomas, which could impede its growth in a rapidly evolving market.

ESLA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Estrella Immunopharma Inc (ESLA) Forecast

Analysts have given ESLA a Strong Buy based on their latest research and market trends.

According to 1 analysts, ESLA has a Strong Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Estrella Immunopharma Inc (ESLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.